Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

Cell

Volumn 119, Issue 6, 2004, Pages 847-860

  Olive, Kenneth P ^a   Tuveson, David A ^b   Ruhe, Zachary C ^a   Yin, Bob ^a   Willis, Nicholas A ^a   Bronson, Roderick T ^c   Crowley, Denise ^a   Jacks, Tyler ^a,d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c TUFTS UNIVERSITY   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ALLELE; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; BIOENGINEERING; CARCINOMA; CODON; CONTROLLED STUDY; DISEASE COURSE; FAMILIAL CANCER; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; HUMAN; MOUSE; MUTANT; NONHUMAN; ONCOGENE; PHYSIOLOGY; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WILD TYPE;

ANIMALIA;

EID: 10944236962     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2004.11.004     Document Type: Article

References (56)

1. Aurelio O.N., Kong X.T., Gupta S., Stanbridge E.J. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. Mol. Cell. Biol. 20:2000;770-778
2. Baker S.J., Preisinger A.C., Jessup J.M., Paraskeva C., Markowitz S., Willson J.K., Hamilton S., Vogelstein B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 50:1990;7717-7722
3. Birch J.M., Blair V., Kelsey A.M., Evans D.G., Harris M., Tricker K.J., Varley J.M. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene. 17:1998;1061-1068
4. Cadwell C., Zambetti G.P. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene. 277:2001;15-30
5. Casciano I., Mazzocco K., Boni L., Pagnan G., Banelli B., Allemanni G., Ponzoni M., Tonini G.P., Romani M. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ. 9:2002;246-251
6. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex. understanding tumorigenic mutations Science. 265:1994;346-355
7. Cordon-Cardo C., Latres E., Drobnjak M., Oliva M.R., Pollack D., Woodruff J.M., Marechal V., Chen J., Brennan M.F., Levine A.J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54:1994;794-799
8. DeLeo A.B., Jay G., Appella E., Dubois G.C., Law L.W., Old L.J. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA. 76:1979;2420-2424
9. de Vries A., Flores E.R., Miranda B., Hsieh H.M., van Oostrom C.T., Sage J., Jacks T. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc. Natl. Acad. Sci. USA. 99:2002;2948-2953
10. Di Como C.J., Gaiddon C., Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 19:1999;1438-1449
11. Dittmer D., Pati S., Zambetti G., Chu S., Teresky A.K., Moore M., Finlay C., Levine A.J. Gain of function mutations in p53. Nat. Genet. 4:1993;42-46
12. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A. Jr., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:1992;215-221
13. Eid H., Institoris E., Geczi L., Bodrogi I., Bak M. mdm-2 expression in human testicular germ-cell tumors and its clinical value. Anticancer Res. 19:1999;3485-3490
14. Eliyahu D., Raz A., Gruss P., Givol D., Oren M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature. 312:1984;646-649
15. Finlay C.A., Hinds P.W., Levine A.J. The p53 proto-oncogene can act as a suppressor of transformation. Cell. 57:1989;1083-1093
16. Forrester K., Lupold S.E., Ott V.L., Chay C.H., Band V., Wang X.W., Harris C.C. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene. 10:1995;2103-2111
17. Gaiddon C., Lokshin M., Ahn J., Zhang T., Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 21:2001;1874-1887
18. Halevy O., Michalovitz D., Oren M. Different tumor-derived p53 mutants exhibit distinct biological activities. Science. 250:1990;113-116
19. Harvey M., Vogel H., Morris D., Bradley A., Bernstein A., Donehower L.A. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet. 9:1995;305-311
20. Hibi K., Trink B., Patturajan M., Westra W.H., Caballero O.L., Hill D.E., Ratovitski E.A., Jen J., Sidransky D. AIS is an oncogene amplified in squamous cell carcinoma. Proc. Natl. Acad. Sci. USA. 97:2000;5462-5467
21. Hinds P., Finlay C., Levine A.J. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J. Virol. 63:1989;739-746
22. Hinds P.W., Finlay C.A., Quartin R.S., Baker S.J., Fearon E.R., Vogelstein B., Levine A.J. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells. a comparison of the "hot spot" mutant phenotypes Cell Growth Differ. 1:1990;571-580
23. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science. 253:1991;49-53
24. Hsiao M., Low J., Dorn E., Ku D., Pattengale P., Yeargin J., Haas M. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am. J. Pathol. 145:1994;702-714
25. Hwang S.J., Lozano G., Amos C.I., Strong L.C. Germline p53 mutations in a cohort with childhood sarcoma. sex differences in cancer risk Am. J. Hum. Genet. 72:2003;975-983
26. Irwin M., Marin M.C., Phillips A.C., Seelan R.S., Smith D.I., Liu W., Flores E.R., Tsai K.Y., Jacks T., Vousden K.H., Kaelin W.G. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature. 407:2000;645-648
27. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1994;1-7
28. Jost C.A., Marin M.C., Kaelin W.G. Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature. 389:1997;191-194
29. Kastan M.B., Zhan Q., el-Deiry W.S., Carrier F., Jacks T., Walsh W.V., Plunkett B.S., Vogelstein B., Fornace A.J. Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597
30. Kleihues P., Schauble B., zur Hausen A., Esteve J., Ohgaki H. Tumors associated with p53 germline mutations. a synopsis of 91 families Am. J. Pathol. 150:1997;1-13
31. Kuperwasser C., Hurlbut G.D., Kittrell F.S., Dickinson E.S., Laucirica R., Medina D., Naber S.P., Jerry D.J. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. Am. J. Pathol. 157:2000;2151-2159
32. Lane D.P., Crawford L.V. T antigen is bound to a host protein in SV40-transformed cells. Nature. 278:1979;261-263
33. Lang G.A., Iwakuma T., Suh Y., Liu G., Rao V.A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., et al. Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome. Cell. 119:2004;861-872., this issue
34. Lavigueur A., Maltby V., Mock D., Rossant J., Pawson T., Bernstein A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell. Biol. 9:1989;3982-3991
35. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331
36. Li B., Murphy K.L., Laucirica R., Kittrell F., Medina D., Rosen J.M. A transgenic mouse model for mammary carcinogenesis. Oncogene. 16:1998;997-1007
37. Linzer D.I., Levine A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell. 17:1979;43-52
38. Liu G., McDonnell T.J., Montes de Oca Luna R., Kapoor M., Mims B., El-Naggar A.K., Lozano G. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc. Natl. Acad. Sci. USA. 97:2000;4174-4179
39. Marin M.C., Jost C.A., Brooks L.A., Irwin M.S., O'Nions J., Tidy J.A., James N., McGregor J.M., Harwood C.A., Yulug I.G., et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 25:2000;47-54
40. O'Gorman S., Dagenais N.A., Qian M., Marchuk Y. Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells. Proc. Natl. Acad. Sci. USA. 94:1997;14602-14607
41. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature. 358:1992;80-83
42. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., Hainaut P. The IARC TP53 database. new online mutation analysis and recommendations to users Hum. Mutat. 19:2002;607-614
43. Parada L.F., Land H., Weinberg R.A., Wolf D., Rotter V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature. 312:1984;649-651
44. Peller S. Clinical implications of p53. effect on prognosis, tumor progression and chemotherapy response Semin. Cancer Biol. 8:1998;379-387
45. Purdie C.A., Harrison D.J., Peter A., Dobbie L., White S., Howie S.E., Salter D.M., Bird C.C., Wyllie A.H., Hooper M.L., et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene. 9:1994;603-609
46. Sah V.P., Attardi L.D., Mulligan G.J., Williams B.O., Bronson R.T., Jacks T. A subset of p53-deficient embryos exhibit exencephaly. Nat. Genet. 10:1995;175-180
47. Shaulsky G., Goldfinger N., Rotter V. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res. 51:1991;5232-5237
48. Strano S., Munarriz E., Rossi M., Cristofanelli B., Shaul Y., Castagnoli L., Levine A.J., Sacchi A., Cesareni G., Oren M., Blandino G. Physical and functional interaction between p53 mutants and different isoforms of p73. J. Biol. Chem. 275:2000;29503-29512
49. Todaro G.J., Green H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established cell lines. J. Cell Biol. 17:1963;299-313
50. Tuveson D.A., Shaw A.T., Willis N.A., Silver D.P., Jackson E.L., Chang S., Mercer K.L., Grochow R., Hock H., Crowley D., et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell. 5:2004;375-387
51. Ventura A., Meissner A., Dillon C.P., McManus M., Sharp P.A., Van Parijs L., Jaenisch R., Jacks T. Cre-lox-regulated conditional RNA interference from transgenes. Proc. Natl. Acad. Sci. USA. 101:2004;10380-10385
52. Wang X.J., Greenhalgh D.A., Jiang A., He D., Zhong L., Medina D., Brinkley B.R., Roop D.R. Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis. Oncogene. 17:1998;35-45
53. Webley K.M., Shorthouse A.J., Royds J.A. Effect of mutation and conformation on the function of p53 in colorectal cancer. J. Pathol. 191:2000;361-367
54. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M.D., Dotsch V., Andrews N.C., Caput D., McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell. 2:1998;305-316
55. Yewdell J.W., Gannon J.V., Lane D.P. Monoclonal antibody analysis of p53 expression in normal and transformed cells. J. Virol. 59:1986;444-452
56. Zhou M., Yeager A.M., Smith S.D., Findley H.W. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood. 85:1995;1608-1614